Cocrystal Pharma and RFS Pharma complete merger
USA-based biotech firm Cocrystal Pharma (OTC BB: COCP) has announced the closing of its merger with RFS Pharma, a privately owned biotech company founded by renowned drug developer, Raymond Schinazi.
Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases. The shareholders of Cocrystal and of RFS Pharma each own around 50% of the combined company on a fully-diluted basis following the merger.
Raymond Schinazi, founder and chairman of RFS Pharma, said: "This merger will produce significant advances in innovation and research productivity. We are excited to join forces with Cocrystal to extend our product portfolio. The skill set and technology that the Cocrystal team brings to the combined company is highly synergistic with RFS Pharma's programs. Together, we will be able to flourish as an organization that can accelerate progress towards drug approval of novel treatments and cures for serious viral diseases."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze